Laboratory Medicine ›› 2023, Vol. 38 ›› Issue (10): 1003-1005.DOI: 10.3969/j.issn.1673-8640.2023.10.018
Previous Articles Next Articles
Received:2022-06-01
Revised:2023-01-12
Online:2023-10-30
Published:2023-12-18
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2023.10.018
| [1] |
ROLFO C, MACK P C, SCAGLIOTTI G V, et al. Liquid biopsy for advanced non-small cell lung cancer(NSCLC):a statement paper from the IASLC[J]. J Thorac Oncol, 2018, 13(9):1248-1268.
DOI URL |
| [2] |
CUI S, YE L, WANG H, et al. Use of SuperARMS EGFR mutation detection kit to detect EGFR in plasma cell-free DNA of patients with lung adenocarcinoma[J]. Clin Lung Cancer, 2018, 19(3):e313-e322.
DOI URL |
| [3] |
WU W, CAO Z, ZHANG W, et al. Comparison of the SuperARMS and ARMS for detecting EGFR mutations in liquid-based cytology specimens from NSCLC patients[J]. Diagn Pathol, 2020, 15(1):9.
DOI |
| [4] |
WU L R, CHEN S X, WU Y, et al. Multiplexed enrichment of rare DNA variants via sequence-selective and temperature-robust amplification[J]. Nat Biomed Eng, 2017, 1:714-723.
DOI PMID |
| [5] | SKRONSKI M, CHOROSTOWSKA-WYNIMKO J, SZCZEPULSKA E, et al. Reliable detection of rare mutations in EGFR gene codon L858 by PNA-LNA PCR clamp in non-small cell lung cancer[J]. Adv Exp Med Biol, 2013, 756:321-331. |
| [6] |
AGGARWAL C, ROLFO C D, OXNARD G R, et al. Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice[J]. Nat Rev Clin Oncol, 2021, 18(1):56-62.
DOI |
| [7] |
EVRARD S M, TARANCHON-CLERMONT E, ROUQUETTE I, et al. Multicenter evaluation of the fully automated PCR-based idylla EGFR mutation assay on formalin-fixed,paraffin-embedded tissue of human lung cancer[J]. J Mol Diagn, 2019, 21(6):1010-1024.
DOI URL |
| [8] |
KOBAYASHI Y, MITSUDOMI T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy[J]. Cancer Sci, 2016, 107(9):1179-1186.
DOI URL |
| [9] |
KOBAYASHI Y, TOGASHI Y, YATABE Y, et al. EGFR exon 18 mutations in lung cancer:molecular predictors of augmented sensitivity to afatinib or neratinib as compared with first- or third-generation TKIs[J]. Clin Cancer Res, 2015, 21(23):5305-5313.
DOI URL |
| [10] |
TRUINI A, STARRETT J H, STEWART T, et al. The EGFR exon 19 mutant L747-A750>P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma[J]. Clin Cancer Res, 2019, 25(21):6382-6391.
DOI URL |
| [11] |
WEI Q, ZHANG J, CHEN D, et al. Primary resistance to gefitinib in a patient with lung adenocarcinoma harboring an EGFR exon 19 L747-A750>P mutation[J]. Lung Cancer, 2020, 148:175-176.
DOI URL |
| [12] | FDA broadens afatinib indication to previously untreated, metastatic NSCLC with other non-resistant EGFR mutations[EB/OL]. (2018-01-16)[2022-06-01]. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-broadens-afatinib-indication-previously-untreated-metastatic-nsclc-other-non-resistant-egfr. |
| [13] |
QIN Y, JIAN H, TONG X, et al. Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors[J]. Mol Oncol, 2020, 14(8):1695-1704.
DOI PMID |
| [14] |
SAXON J A, SHOLL L M, JÄNNE P A. EGFR L858M/L861Q cis mutations confer selective sensitivity to afatinib[J]. J Thorac Oncol, 2017, 12(5):884-889.
DOI PMID |
| [15] |
BEJJANKI H, BISHNOI R, REISMAN D. Novel mutation pair L858M/L861Q caused resistance to both first- and third-generation EGFR inhibitors,but was found to be sensitive to the combination of lapatinib and erbitux[J]. J Thorac Oncol, 2017, 12(10):e169-e170.
DOI URL |
| [1] | FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114. |
| [2] | SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120. |
| [3] | LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129. |
| [4] | YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140. |
| [5] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
| [6] | CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152. |
| [7] | . [J]. Laboratory Medicine, 2023, 38(12): 1153-1156. |
| [8] | . [J]. Laboratory Medicine, 2023, 38(12): 1157-1159. |
| [9] | WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166. |
| [10] | YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172. |
| [11] | DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176. |
| [12] | GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182. |
| [13] | . [J]. Laboratory Medicine, 2023, 38(12): 1183-1185. |
| [14] | . [J]. Laboratory Medicine, 2023, 38(12): 1186-1190. |
| [15] | . [J]. Laboratory Medicine, 2023, 38(12): 1191-1194. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
